Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update

References

• Papi A, Brightling C, Pedersen SE, et al. Asthma. Lancet. 2018;391(10122):783–800.
   PubMed Web of Science ®Google Scholar
• McCracken JL, Veeranki SP, Ameredes BT, et al. Diagnosis and management of asthma in adults: a review. JAMA. 2017;318(3):279–290.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Canonica GW, Winders TA, et al. A charter to improve patient care in severe asthma. Adv Ther. 2018;35(10):1485–1496.
   PubMed Web of Science ®Google Scholar
• Dean K, Niven R. Asthma phenotypes and endotypes: implications for personalised therapy. BioDrugs. 2017 Sep 6;31(5):393–408. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2018 Apr 6;18(7):454–466. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Arron JR, Choy DF, Scheerens H, et al. Non-invasive biomarkers that predict treatment benefit from biologic therapies in asthma. Ann Am Thorac Soc. 2013;10(10 Suppl):S206–13.
   PubMedGoogle Scholar
• Talini D, Novelli F, Bacci E, et al. Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study. BMJ Open. 2015;5(1):e005748.
   PubMed Web of Science ®Google Scholar
• Price D, Wilson AM, Chisholm A, et al. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. J Asthma Allergy. 2016;9:1–12.
   PubMed Web of Science ®Google Scholar
• Ortega H, Yancey SW, Keene ON, et al. Asthma exacerbations associated with lung function decline in patients with severe eosinophilic asthma. J Allergy Clin Immunol Pract. 2018;6(3):980–986. .
   PubMed Web of Science ®Google Scholar
• Tran TN, Khatry DB, Ke X, et al. High blood eosinophil count is associated with more frequent asthma attacks in asthma patients. Allergy Asthma Immunol. 2014;113:19–24.
   PubMed Web of Science ®Google Scholar
• Zeiger RS, Schatz M, Li Q, et al. Elevated blood eosinophil level is a risk factor for exacerbations in adult persistent asthma. Am J Respir Crit Care Med. 2014;2(6):741–750. 189.
   Google Scholar
• Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol. 2013;13(1):9–22.
   PubMed Web of Science ®Google Scholar
• Nissim Ben Efraim AH, Levi-Schaffer F. Tissue remodeling and angiogenesis in asthma: the role of the eosinophil. Ther Adv Respir Dis. 2008;2(3):163–171.
   PubMedGoogle Scholar
• Pelaia C, Paoletti G, Puggioni F, et al. Interleukin-5 in the pathophysiology of severe asthma. Front Physiol. 2019;10:1514.
   PubMed Web of Science ®Google Scholar
• Walsh GM. Reslizumab in the treatment of severe eosinophilic asthma: an update. Immunotherapy. 2018;10(8):695–698.
   PubMed Web of Science ®Google Scholar
• Corren J. Inhibition of interleukin-5 for the treatment of eosinophilic diseases. Discovery Med. 2012;13:305–312.
   PubMed Web of Science ®Google Scholar
• Ghazi A, Trikha A, Calhoun WJ. Benralizumab–a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity–a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012;12(1):113–118.
   PubMed Web of Science ®Google Scholar
• Walsh GM. Mepolizumab based therapy in Asthma – an update. Current Opin Allergy Clin Immunol. 2015;15(4):392–396.
   PubMed Web of Science ®Google Scholar
• Menzella F, Lusuardi M, Montanari G, et al. Clinical usefulness of mepolizumab in severe eosinophilic asthma. Ther Clin Risk Manag. 2016;12:907–916.
   PubMed Web of Science ®Google Scholar
• Cavaliere C, Frati F, Ridolo E, et al. The spectrum of therapeutic activity of mepolizumab. Expert Rev Clin Immunol. 2019;15(9):959–967.
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma, N. Engl J Med. 2009;360(10):973–984.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. .
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198.
   PubMed Web of Science ®Google Scholar
• EH B, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Eng J Med. 2014;371(13):1189–1197.
   PubMed Web of Science ®Google Scholar
• Lugogo N, Domingo C, Chanez P, et al. Long term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study, Clin. Therapeut. 2016;38(9):2058–2070.
   Google Scholar
• Chupp GL, Bradford ES, Albers FC, et al., Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 5(5): 390–400. 2017.
   PubMed Web of Science ®Google Scholar
• Bateman ND, Shahi A, Feeley KM, et al. Activated eosinophils in nasal polyps: a comparison of asthmatic and non-asthmatic patients. Clin Otolaryngol. 2005;30(3):221–225.
   PubMed Web of Science ®Google Scholar
• Howarth P, Chupp G, Nelsen LM, et al. Severe eosinophilic asthma with nasal polyposis: a phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy. J Allergy Clin Immunol. 2020 Feb 19;145(6):1713–1715. S0091-6749(20)30194-9. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang S, Li DW, et al. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS One. 2013;8(3):e59872.
   PubMed Web of Science ®Google Scholar
• Yancey SW, Ortega HG, Keene ON, et al. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. J Allergy Clin Immunol. 2016;4:pii: S0091-6749(16)30891–0. 10.1016/j.jaci.2016.08.008. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Cockle SM, Stynes G, Gunsoy NB, et al. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: an indirect treatment comparison. Respir Med. 2017;123:140–148.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, et al. Clinical outcomes in patients with severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a combined analysis of the DREAM and MENSA studies. Lancet Resp Med. 2016;4(7):549–556.
   PubMed Web of Science ®Google Scholar
• Farah CS, Badal T, Reed N, et al. Mepolizumab improves small airway function in severe eosinophilic asthma. Respir Med. 2019;148:49–53.
   PubMed Web of Science ®Google Scholar
• Verbanck S, Schuerman D, Noppe M, et al. Evidence of acinar airway involvement in asthma. Am J Respir Crit Care Med. 1999;159(5):1545–1550.
   PubMed Web of Science ®Google Scholar
• Bruno S, Gianna C, Elena B, et al. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: results of a single-centre observational study. Pulmonary Pharmacol Therap. 2018;53:1–5.
   PubMed Web of Science ®Google Scholar
• Llanos JP, Ortega H, Bogart M, et al. Real-world effectiveness of mepolizumab in patients with severe asthma: an examination of exacerbations and costs. J Asthma Allergy 2020;13:77–87. eCollection 2020. PMID: 32099413.
   Google Scholar
• Schleich F, Graff S, Nekoee H, et al. Real-word experience with mepolizumab: does it deliver what it has promised? Clin Exp Allergy. 2020 Mar 21;50(6):687–695. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Taillé C, Chanez P, Devouassoux G, et al. Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a french early access programme. Eur Respir J. 2020 Apr 2:1902345. Online ahead of print.PMID: 32241829. 10.1183/13993003.02345-2019
   PubMed Web of Science ®Google Scholar
• van Toor JJ, van der Mark SC, Kappen JH, et al. Add-on mepolizumab therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety. J Asthma. 2020 Feb 12:1–8 Online ahead of print.PMID: 31999203. 10.1080/02770903.2020.1723623.
   PubMed Web of Science ®Google Scholar
• Kallur L, Gonzalez-Estrada A, Eidelman F, et al. Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults. Expert Opin Drug Metab Toxicol. 2017;13(12):1275–1280.
   PubMed Web of Science ®Google Scholar
• Pelaia G, Vatrella A, Busceti MT. Role of biologics in severe eosinophilic asthma - focus on reslizumab. Ther Clin Risk Manag. 2016;12:1075–1082.
   PubMed Web of Science ®Google Scholar
• Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125–1132.
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366.
   PubMed Web of Science ®Google Scholar
• Corren J, Weinstein S, Janka L, et al., Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 150(4): 799–810. 2016.
   PubMed Web of Science ®Google Scholar
• Bjermer L, Lemiere C, Maspero J, et al., Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 150(4): 789–798. 2016.
   PubMed Web of Science ®Google Scholar
• Brusselle G, Germinaro M, Weiss S, et al. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulm Pharmacol Ther. 2017;43:39–45.
   PubMed Web of Science ®Google Scholar
• Murphy K, Jacobs J, Bjermer L, et al., Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract. 5(6): 1572–1581. 2017.
   PubMed Web of Science ®Google Scholar
• Ibrahim H, O’Sullivan R, Casey D, et al. The effectiveness of Reslizumab in severe asthma treatment: a real-world experience. Respir Res. 2019;20(1):289.
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Virchow JC, Murphy K, et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2020 May;8(5):461–474. Epub 2020 Feb 14.PMID: 32066536.
   PubMed Web of Science ®Google Scholar
• Maselli DJ, Roberts L, Peters JI. Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use. Ther Clin Risk Manag. 2018;14:2059–2068.
   PubMed Web of Science ®Google Scholar
• Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344–1353.
   PubMed Web of Science ®Google Scholar
• Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab onairway eosinophils in asthmatic patients with sputum eosinophilia. J AllergyClin Immunol. 2013 Nov;132(5):1086–1096.
   PubMed Web of Science ®Google Scholar
• Pham TH, Damera G, Newbold P, et al. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016;111:21–29.
   PubMed Web of Science ®Google Scholar
• Nowak RM, Parker JM, Silverman RA, et al. A randomized trial of benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, after acute asthma. Am J Emerg Med. 2015;33(1):14–20.
   PubMed Web of Science ®Google Scholar
• Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879–890.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al., Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 388(10056): 2115–2127. 2016.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al., Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 388(10056): 2128–2141. 2016.
   PubMed Web of Science ®Google Scholar
• Chipps BE, Newbold P, Hirsch I, et al. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2018;120(5):504–511.
   PubMed Web of Science ®Google Scholar
• Goldman M, Hirsch I, Zangrilli JG, et al. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies. Curr Med Res Opin. 2017;33(9):1605–1613.
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al., Oral Glucocorticoid-Sparing Effect ofBenralizumab in Severe Asthma. N Engl J Med. 376(25): 2448–2458. 2017.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, FitzGerald JM, Bleecker ER, et al. Benralizumab for patientswith mild to moderate, persistent asthma (BISE): a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2017;5(7):568–576.
   PubMed Web of Science ®Google Scholar
• Panettieri RA Jr, Welte T, Shenoy KV, et al. Onset of effect, changes in airflow obstruction and lung volume, and health-related quality of life improvements with benralizumab for patients with severe eosinophilic asthma: phase iiib randomized, controlled trial (SOLANA). J Asthma Allergy. 2020;13:115–126.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6(1):51–64.
   PubMed Web of Science ®Google Scholar
• Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7(1):46–59.
   PubMed Web of Science ®Google Scholar
• Bourdin A, Shaw D, Menzies-Gow A, et al. Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma. J Asthma. 2019;26:1–9. [Epub ahead of print].
   Google Scholar
• Chipps BE, Hirsch I, Trudo F, et al. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma. Ann Allergy Asthma Immunol. 2020;124(1):79–86. Epub 2019 Oct 15.
   PubMed Web of Science ®Google Scholar
• Mathur SK, Modena BD, Coumou H, et al. Postbronchodilator lung function improvements with benralizumab for patients with severe asthma. Allergy. 2020 Jan 10;75(6):1507–1510.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Wechsler ME, FitzGerald JM, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018 Oct 18;52(4):1800936. Print 2018 Oct.PMID: 30139780.
   PubMed Web of Science ®Google Scholar
• Pelaia C, Busceti MT, Vatrella A, et al. Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma. SAGE Open Med Case Rep. 2020;8:2050313X20906963. eCollection 2020. PMID: 32110408.
   PubMed Web of Science ®Google Scholar
• McQueen RB, Sheehan DN, Whittington MD, et al. Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations. Pharmacoeconomics. 2018;36(8):957–971.
   PubMed Web of Science ®Google Scholar
• Tan R, Liew MF, Lim HF, et al. Promises and challenges of biologics for severe asthma. Biochem Pharmacol. 2020 May 8:114012 Online ahead of print. 10.1016/j.bcp.2020.114012.
   PubMed Web of Science ®Google Scholar
• Bakakos A, Loukides S, Bakakos P. Severe eosinophilic asthma. J Clin Med. 2019 Sep 2;8(9):1375.
   PubMed Web of Science ®Google Scholar
• Whittington MD, McQueen RB, Ollendorf DA, et al. Assessing the value ofmepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Annals Allergy Asthma Immunol. 2017;118(2):220–225.
   PubMed Web of Science ®Google Scholar
• Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020 May;75(5):1023–1042. Epub 2020 Feb 24.PMID: 32034960.
   PubMed Web of Science ®Google Scholar